knowledge -WSS

knowledge

author：knowledge 2025-09-29 19:58:41 - browse：71157

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Biotech investment managers search for lucrative opportunities

knowledge

hotspot

WSS

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Readout Newsletter: Illumina, CRISPR, Regeneron

Pregnancy ages women, but effects reverse after delivery

Testing GLP

Venture capitalist Bob Kocher on the state of digital health

With Wegovy coverage, Medicare patients may face high costs

hotspot

knowledge

knowledge

Hollywood unions extend contract negotiations for actors

Military medical care influenced by rank and race, new study finds

The cancer drug shortage isn’t new — and neither are the solutions

Military medical care influenced by rank and race, new study finds

Bright Health sells Medicare Advantage business to Molina

Yancopoulos of Regeneron works to expand Dupixent success

Medicare details structure of new drug price negotiation program

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

New air purifier tech could be key to improving indoor air quality

Pregnancy ages women, but effects reverse after delivery

hotspot

With measles on the rise, a personal story of a devastating disease

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Pregnancy ages women, but effects reverse after delivery

CRISPR technology availability, affordability needs to be expanded

Diabetes management: Digital health tools fall short, study says

explore

knowledge

hotspot

leisure time